# A Study of Talazoparib in Men With DNA Repair Defects and Metastatic Castration-Resistant Prostate Cancer

> **NCT03148795** · PHASE2 · COMPLETED · sponsor: **Pfizer** · enrollment: 128 (actual)

## Conditions studied

- Prostate Cancer

## Interventions

- **DRUG:** Talazoparib

## Key facts

- **NCT ID:** NCT03148795
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-07-04
- **Primary completion:** 2020-09-04
- **Final completion:** 2023-03-31
- **Target enrollment:** 128 (ACTUAL)
- **Last updated:** 2024-04-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03148795

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03148795, "A Study of Talazoparib in Men With DNA Repair Defects and Metastatic Castration-Resistant Prostate Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03148795. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*